Synergy CHC Secures Highly Dilutive $36M Equity Line of Credit and Issues Warrants Amidst Financial Distress
SNYR sits 26% above its 52-week low of $0.299 on elevated volume (2.1× avg).
Summary
Synergy CHC Corp. secured a highly dilutive $36 million equity line of credit and issued warrants, a critical financing move for the financially distressed company, but at a significant cost to existing shareholders.
Key Events · Financing and Capital Events · SNYR
-
Secured Equity Line of Credit
The company entered into an equity purchase agreement with Hudson Global Ventures, LLC, allowing it to sell up to $36,000,000 of common stock over a 24-month period. This follows the S-3 registration filed 3 days ago on 2026-04-17 seeking shareholder approval for dilutive equity plans.
-
Highly Dilutive Terms
Shares will be sold at a variable discount, specifically 95% of the lesser of certain lowest traded or closing prices, which is highly dilutive for existing shareholders.
-
Warrant Issuance
As consideration for the agreement, the company issued a common stock purchase warrant for 1,540,000 shares at an exercise price of $0.01 per share, exercisable for five years. These warrants represent significant potential dilution.
-
Shareholder Approval Required for Full Amount
Issuance of shares under the agreement is limited by an "Exchange Cap" of 2,978,486 shares unless shareholder approval is obtained, meaning the majority of the $36 million facility is contingent on future shareholder action.
Analysis · SNYR · Life Sciences
This 8-K details a critical financing agreement for Synergy CHC Corp., a company facing severe financial challenges. The ability to raise up to $36 million through an equity line of credit (ELOC) provides a potential lifeline, especially given the recent term loan amendment requiring a $10 million equity raise by September 2026. However, the terms are highly unfavorable for existing shareholders, with shares to be sold at a discount to market prices. The issuance of 1,540,000 warrants at a nominal exercise price further exacerbates potential dilution. While the full $36 million is contingent on shareholder approval beyond an initial "Exchange Cap," this agreement signals the company's urgent need for capital and its willingness to accept highly dilutive terms to secure it. This event is a significant step in the company's ongoing efforts to address its liquidity issues and meet its debt obligations, but at a substantial cost to equity value.
How filings like this one have moved
In the 30 days to Oct 11, 2026, 43.2% of the 303 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.62%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNYR was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8M. The 52-week trading range was $0.30 to $4.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.